Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apyx Medical (APYX) Accumulated Expenses (2016 - 2025)

Apyx Medical (APYX) has disclosed Accumulated Expenses for 16 consecutive years, with $8.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Accumulated Expenses rose 5.97% year-over-year to $8.2 million, compared with a TTM value of $8.2 million through Dec 2025, up 5.97%, and an annual FY2025 reading of $8.2 million, up 5.97% over the prior year.
  • Accumulated Expenses was $8.2 million for Q4 2025 at Apyx Medical, up from $7.3 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $10.3 million in Q4 2021 and bottomed at $6.8 million in Q1 2025.
  • Average Accumulated Expenses over 5 years is $8.1 million, with a median of $7.9 million recorded in 2023.
  • The sharpest move saw Accumulated Expenses surged 41.34% in 2021, then dropped 19.77% in 2024.
  • Year by year, Accumulated Expenses stood at $10.3 million in 2021, then decreased by 13.21% to $8.9 million in 2022, then rose by 8.21% to $9.7 million in 2023, then decreased by 19.77% to $7.8 million in 2024, then grew by 5.97% to $8.2 million in 2025.
  • Business Quant data shows Accumulated Expenses for APYX at $8.2 million in Q4 2025, $7.3 million in Q3 2025, and $7.3 million in Q2 2025.